Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk of SARS-CoV-2 infection and severe COVID-19 in hematological patients who received or not pre-exposure prophylaxis with tixagevimab/cilgavimab: a target trial emulation.
Falcone M, Tiseo G, Marchetti G, Kalo J, Galfo V, Occhineri S, Almerigogna F, Matucci T, Riccardi N, Suardi LR, Rina I, Sijoni L, Caparello MC, Cassano Cassano R, Del Giudice ML, Franciosa M, Facella F, Tancredi G, Fazzi R, Galimberti S. Falcone M, et al. Among authors: galfo v. Leuk Lymphoma. 2024 Jun 4:1-8. doi: 10.1080/10428194.2024.2361099. Online ahead of print. Leuk Lymphoma. 2024. PMID: 38832710
Real-world experience with meropenem/vaborbactam for the treatment of infections caused by ESBL-producing Enterobacterales and carbapenem-resistant Klebsiella pneumoniae.
Tiseo G, Galfo V, Riccardi N, Suardi LR, Pogliaghi M, Giordano C, Leonildi A, Barnini S, Falcone M. Tiseo G, et al. Among authors: galfo v. Eur J Clin Microbiol Infect Dis. 2024 Feb 20. doi: 10.1007/s10096-024-04758-2. Online ahead of print. Eur J Clin Microbiol Infect Dis. 2024. PMID: 38376634
Salvage therapy with sulbactam/durlobactam against cefiderocol-resistant Acinetobacter baumannii in a critically ill burn patient: clinical challenges and molecular characterization.
Tiseo G, Giordano C, Leonildi A, Riccardi N, Galfo V, Limongi F, Nicastro M, Barnini S, Falcone M. Tiseo G, et al. Among authors: galfo v. JAC Antimicrob Resist. 2023 Jun 14;5(3):dlad078. doi: 10.1093/jacamr/dlad078. eCollection 2023 Jun. JAC Antimicrob Resist. 2023. PMID: 37325251 Free PMC article.
Pharyngeal and cutaneous diphtheria: a tail of a refugee.
Galfo V, Riccardi N, Leonildi A, Falcone M, Barnini S. Galfo V, et al. Infection. 2023 Oct;51(5):1599-1600. doi: 10.1007/s15010-023-01990-4. Epub 2023 Jan 31. Infection. 2023. PMID: 36719633 No abstract available.
Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Clinic Experience.
Tiseo G, Barbieri C, Galfo V, Occhineri S, Matucci T, Almerigogna F, Kalo J, Sponga P, Cesaretti M, Marchetti G, Forniti A, Caroselli C, Ferranti S, Pogliaghi M, Polidori M, Fabiani S, Verdenelli S, Tagliaferri E, Riccardi N, Suardi LR, Carmignani C, Batini S, Puccetti L, Iapoce R, Menichetti F, Falcone M. Tiseo G, et al. Among authors: galfo v. Infect Dis Ther. 2023 Jan;12(1):257-271. doi: 10.1007/s40121-022-00729-2. Epub 2022 Nov 28. Infect Dis Ther. 2023. PMID: 36441485 Free PMC article.
20 results